SLC5A2 and metabolic dysfunction-associated steatohepatitis: Although the mechanism behind this improvement is unclear, there is evidence that SGLT2 inhibitors can reduce liver inflammation and prevent the progression of liver fibrosis in mouse models of non-alcoholic steatohepatitis and diabetes [13].